More importantly, we demonstrate, for the first time, that PRC1 can be targeted by piperlongumine (PL), an agent that has been previously proved to suppress gastric cancer cells by our group 17, via a p53‐dependent mechanism. This evidence concerns the gene TP53 and gastric cancer.